C2729T mutation associated with HBV mother-to-child transmission reduces HBV production via suppressing LHBs expression

Virulence. 2023 Dec;14(1):2189676. doi: 10.1080/21505594.2023.2189676.

Abstract

Mother-to-child transmission (MTCT) is still the main route of hepatitis B virus (HBV) infection. However, the virological factors affecting HBV MTCT have not been fully elucidated. In this study, based on a prospective cohort of mother-infant pairs with positive maternal hepatitis B surface antigen (HBsAg), we found that the average nucleotide mutation rate of HBV preS1 promoter (SPI) region in the immunoprophylaxis success group was significantly higher than that in the immunoprophylaxis failure group. Among the nucleotide mutations of the HBV SPI region, the C2729T mutation had the highest frequency. Next, we found that the C2729T mutation promoted HBsAg release but reduced HBV production by suppressing the expression of large hepatitis B surface antigen (LHBs), and overexpressing LHBs could rescue this phenomenon. Based on the fact that the C2729T mutation could alter the binding site of hepatocyte nuclear factor 1 (HNF1) in the HBV SPI region, we uncovered that such an alteration could downregulate the transcriptional activity of SPI by attenuating the binding ability of HNF1 and HBV SPI region. This study suggests that HBV C2729T mutation may contribute to the immunoprophylaxis success of HBV MTCT by reducing HBV production, which supplements the virological factors affecting HBV MTCT.

Keywords: Hepatitis B virus; hepatocyte nuclear factor 1; large hepatitis B surface antigen; mother-to-child transmission; preS1 promoter.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • DNA, Viral / genetics
  • Female
  • Hepatitis B Surface Antigens / genetics
  • Hepatitis B Surface Antigens / therapeutic use
  • Hepatitis B e Antigens / genetics
  • Hepatitis B e Antigens / therapeutic use
  • Hepatitis B virus / genetics
  • Hepatitis B* / drug therapy
  • Hepatitis B* / genetics
  • Hepatitis B* / prevention & control
  • Humans
  • Infant
  • Infectious Disease Transmission, Vertical / prevention & control
  • Mutation
  • Nucleotides / therapeutic use
  • Pregnancy
  • Pregnancy Complications, Infectious*
  • Prospective Studies

Substances

  • Hepatitis B Surface Antigens
  • Hepatitis B e Antigens
  • Nucleotides
  • DNA, Viral

Grants and funding

This research was funded by grants from the Special Fund of Peking University Health Science Center (BMU2021RCZX013), the National Natural Science Foundation of China (81974309 and 82172251), and the National Major Scientific and Technological Special Project during the Thirteenth Five-Year Plan Period (2017ZX10201201003)